K-Cell Biotech Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 8

K-Cell Biotech General Information

Description

Developer of biopharmaceutical technology designed for vaccines.The company's vaccines include human rabies vaccine (chicken embryo fibroblast), new genotype MMR combination vaccine, inactivated rotavirus vaccine and respiratory syncytial virus vaccine, enabling users to improve human health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • No. 1136, Langong Road
  • Jinshan Industrial Park
  • Shanghai
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • No. 1136, Langong Road
  • Jinshan Industrial Park
  • Shanghai
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

K-Cell Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 28-Oct-2022 Completed Generating Revenue
1. Early Stage VC 04-Jun-2021 Completed Generating Revenue
To view K-Cell Biotech’s complete valuation and funding history, request access »

K-Cell Biotech Patents

K-Cell Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022188783-A1 Construction of f gene-replaced chimeric measles attenuated strain Inactive 10-Mar-2021
WO-2022188784-A1 Construction of h-gene-replaced chimeric measles attenuated strain Inactive 10-Mar-2021
EP-4056983-A1 Device for evaluating neurovirulence of mumps virus Pending 04-Nov-2019
EP-4056983-A4 Device for evaluating neurovirulence of mumps virus Pending 04-Nov-2019
US-20220404359-A1 Device for evaluating neurovirulence of mumps virus Pending 04-Nov-2019 G01N1/30
To view K-Cell Biotech’s complete patent history, request access »

K-Cell Biotech Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDH Investments PE/Buyout Minority
Dongwu Securities Corporation Minority
Haitong Securities (Shanghai) Investment Bank Minority
Shiyu Capital Venture Capital Minority
Zhenji Capital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

K-Cell Biotech FAQs

  • When was K-Cell Biotech founded?

    K-Cell Biotech was founded in 2017.

  • Where is K-Cell Biotech headquartered?

    K-Cell Biotech is headquartered in Shanghai, China.

  • What industry is K-Cell Biotech in?

    K-Cell Biotech’s primary industry is Drug Discovery.

  • Is K-Cell Biotech a private or public company?

    K-Cell Biotech is a Private company.

  • What is K-Cell Biotech’s current revenue?

    The current revenue for K-Cell Biotech is .

  • Who are K-Cell Biotech’s investors?

    CDH Investments, Dongwu Securities, Haitong Securities (Shanghai), Shiyu Capital, and Zhenji Capital are 5 of 8 investors who have invested in K-Cell Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process